92151-89-8

Basic information

• Product Name: methyl dibenzo[b,d]furan-4-carboxylate
• Synonyms: methyl dibenzo[b,d]furan-4-carboxylate;Dibenzofuran-4-carboxylic acid methyl ester
• CAS NO: 92151-89-8
• Molecular Formula: C14H10O3
• Molecular Weight: 226.2274
• Mol File: 92151-89-8.mol
• Article Data: 3

Chemical Properties

• Melting Point: 142-144 °C
• Boiling Point: 361.4±15.0 °C(Predicted)
• Appearance: /
• Density: 1.268±0.06 g/cm3(Predicted)
• CAS DataBase Reference: methyl dibenzo[b,d]furan-4-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl dibenzo[b,d]furan-4-carboxylate(92151-89-8)
• EPA Substance Registry System: methyl dibenzo[b,d]furan-4-carboxylate(92151-89-8)

Safety Data

• Hazardous Substances Data: 92151-89-8(Hazardous Substances Data)

Upstream product

• 67-56-1 methanol 
• 66283-60-1 dibenzofuran carboxylic acid chloride 
• 2786-05-2 dibenzofuran-4-carboxylic acid 

Downstream Products

• 5410-97-9 3-nitrodibenzofuran 
• 13761-32-5 2-acetyldibenzofuran 

Relevant articles and documents

Pd-Catalyzed Denitrative Intramolecular C-H Arylation

A Pd-catalyzed intramolecular C-H arylation of nitroarenes has been developed. Nitroarenes bearing tethered aryl groups at the ortho-position can be readily prepared in one step from 2-halonitroarenes by a nucleophilic aromatic substitution (SNAr). Under Pd/BrettPhos catalysis, activations of the C-NO2 bond as well as the C-H bond on arenes generated the corresponding biaryl linkage in moderate to excellent yields.

Synthesis and evaluation of some novel dibenzo[b,d]furan carboxylic acids as potential anti-diabetic agents

A series of novel dibenzo[b,d]furan mono-carboxylic acid derivatives were synthesized, characterized and evaluated for their ability to inhibit Protein Tyrosine Phosphatase 1B (PTP1B) in vitro in order to use them as potential anti-diabetic agents. Structure-activity relationship study led to the identification of potent compound 5E which inhibited PTP1B with IC50 value of 82 ± 0.43 nM. Compound 5E was screened in vivo as drug candidate for anti-diabetic activity using rosiglitazone maleate as the standard. Compound 5E showed significant reduction in body weight, fed-state whole blood glucose (WBG), fasting WBG, plasma glucose and plasma cholesterol levels and non-significant reduction in fasting plasma triglyceride levels in ob/ob mice. A series of dibenzo[b,d]furan carboxylic acids were synthesized and evaluated for anti-diabetic activity. Compound 5E inhibited PTP1B with IC50 of 82 nM and reduced WBG and plasma glucose in ob/ob mice.